To address this, we developed a relevant vascular smooth muscle cells (SMC) model by using hiPSC harboring the HDAC9 stroke-associated risk variant to assess HDAC9-mediated phenotypic changes and screen the efficacy of HDAC inhibitors. This evidence concerns the gene HDAC9 and stroke disorder.